XML 35 R26.htm IDEA: XBRL DOCUMENT
v3.23.2

Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2023
Accounting Policies [Abstract] |
Schedule of Fair Value Measurement of Financial Assets and Liabilities | The following table presents the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands): Schedule of Fair Value Measurement of Financial Assets and Liabilities
|  | As of June 30, 2023 |
|  | Total carrying and estimated fair value |  |  | Quoted prices in active markets (Level 1) |  |  | Significant other observable inputs (Level 2) |  |  | Significant other observable inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable equity securities |  | $ | 530 |  |  | $ | 530 |  |  | $ | - |  |  | $ | - |
Total |  | $ | 530 |  |  | $ | 530 |  |  | $ | - |  |  | $ | - |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration liabilities |  | $ | 29,150 |  |  | $ | - |  |  | $ | - |  |  | $ | 29,150 |
Total |  | $ | 29,150 |  |  | $ | - |  |  | $ | - |  |  | $ | 29,150 |
The following table presents the Company’s assets and liabilities, measured and recognized at fair value on a recurring basis, classified under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):
|  | As of December 31, 2022 |
|  | Total carrying and estimated fair value |  |  | Quoted prices in active markets (Level 1) |  |  | Significant other observable inputs (Level 2) |  |  | Significant other observable inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Marketable equity securities |  | $ | 433 |  |  | $ | 433 |  |  | $ | - |  |  | $ | - |
Total |  | $ | 433 |  |  | $ | 433 |  |  | $ | - |  |  | $ | - |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration liabilities |  | $ | 45,662 |  |  | $ | - |  |  | $ | - |  |  | $ | 45,662 |
Total |  | $ | 45,662 |  |  | $ | - |  |  | $ | - |  |  | $ | 45,662 |
Schedule of Cash and Cash Equivalents and Restricted Cash | Schedule of Cash and Cash Equivalents and Restricted Cash
|  | June 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
Cash and cash equivalents |  | $ | 17,368 |  |  | $ | 19,993 |
Restricted cash |  |  | 1,700 |  |  |  | 1,700 |
Cash from discontinuing operations |  |  | - |  |  |  | 1,510 |
Cash, cash equivalents and restricted cash shown in the statements of cash flows |  | $ | 19,068 |  |  | $ | 23,203 |
Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock | All common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents the calculation of basic and diluted loss per share of common stock (in thousands): Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss attributable to Oncocyte Corporation |  | $ | (8,333 | ) |  | $ | (8,300 | ) |  | $ | (5,300 | ) |  | $ | (18,591 | )
Dividend on Series A redeemable convertible preferred stock |  |  | (76 | ) |  |  | (29 | ) |  |  | (166 | ) |  |  | (29 | )
Accretion of Series A redeemable convertible preferred stock |  |  | (117 | ) |  |  | (43 | ) |  |  | (257 | ) |  |  | (43 | )
Deemed dividend on Series A redeemable convertible preferred stock |  |  | (118 | ) |  |  | - |  |  |  | (118 | ) |  |  | - |
Net loss attributable to common stockholders - Basic and Diluted |  | $ | (8,644 | ) |  | $ | (8,372 | ) |  | $ | (5,841 | ) |  | $ | (18,663 | )
Net loss attributable to common stockholders - Basic |  | $ | (8,644 | ) |  | $ | (8,372 | ) |  | $ | (5,841 | ) |  | $ | (18,663 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted |  |  | 8,090 |  |  |  | 5,652 |  |  |  | 7,030 |  |  |  | 5,135 |
Basic and diluted net loss per common share |  | $ | (1.07 | ) |  | $ | (1.48 | ) |  | $ | (0.83 | ) |  | $ | (3.63 | )
Basic net loss per common share |  | $ | (1.07 | ) |  | $ | (1.48 | ) |  | $ | (0.83 | ) |  | $ | (3.63 | )
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options |  |  | 483 |  |  |  | 731 |  |  |  | 549 |  |  |  | 657 |
RSUs |  |  | 7 |  |  |  | - |  |  |  | 10 |  |  |  | - |
Warrants |  |  | 820 |  |  |  | 845 |  |  |  | 820 |  |  |  | 845 |
Series A redeemable convertible preferred stock |  |  | 5 |  |  |  | 6 |  |  |  | 5 |  |  |  | 6 |
Total |  |  | 1,315 |  |  |  | 1,582 |  |  |  | 1,384 |  |  |  | 1,508 |
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share |  |  | 1,315 |  |  |  | 1,582 |  |  |  | 1,384 |  |  |  | 1,508 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of cash and cash equivalents. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the effect of income (loss) on basic earnings per share. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration